Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Epifanio Sanchez-Garavito

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Bulletin of the World Health Organization|February 25, 2016
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosisThelma Tupasi, Rajesh Gupta, Manfred Danilovits, et al.
BMC Infectious Diseases|August 29, 2016
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trialMeredith Milstein, Leonid Lecca, Charles Peloquin, et al.
The New England Journal of Medicine|June 8, 2012
Delamanid for multidrug-resistant pulmonary tuberculosisMaria Tarcela Gler, Vija Skripconoka, Epifanio Sanchez-Garavito, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Bulletin of the World Health Organization|February 25, 2016
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosisThelma Tupasi, Rajesh Gupta, Manfred Danilovits, et al.
BMC Infectious Diseases|August 29, 2016
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trialMeredith Milstein, Leonid Lecca, Charles Peloquin, et al.
The New England Journal of Medicine|June 8, 2012
Delamanid for multidrug-resistant pulmonary tuberculosisMaria Tarcela Gler, Vija Skripconoka, Epifanio Sanchez-Garavito, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Pageof 1